Group 1 - The MSCI Nordic countries index experienced a significant drop of 2.4% on February 24, closing at 383.03 points, marking the largest single-day decline since July 29, 2025 [1] - The healthcare sector led the decline, with Novo Nordisk's stock plummeting by 16.5%, making it the worst-performing stock in the Nordic region [1] - The sharp volatility in Novo Nordisk's stock is attributed to disappointing clinical data for its new weight-loss drug CagriSema, which achieved a 23% weight loss over 84 weeks but failed to meet its primary endpoint [1] Group 2 - Morgan Stanley characterized the clinical data results as the "worst-case scenario," while Jefferies highlighted the high dependency of Novo Nordisk's valuation on amycretin, indicating increased commercialization uncertainty [2] - JPMorgan noted that the results confirm Eli Lilly's Zepbound as the clear market leader, which is expected to continue gaining market share [2] - The setback for CagriSema has caused a ripple effect on the European weight-loss drug and GLP-1 sectors, with other companies like Zealand Pharma and Bachem experiencing declines [2] Group 3 - The competitive landscape in the global weight-loss drug market is rapidly differentiating, with Eli Lilly's Zepbound projected to generate $4.2 billion in revenue by Q4 2025, reflecting a 122% year-over-year increase [2] - Eli Lilly has also introduced a new formulation of Zepbound, consolidating a month's dosage into a single injection pen, which has received FDA approval for label expansion [2] - According to Dongfang Securities, Eli Lilly's tirzepatide is expected to achieve sales of $36.507 billion in 2025, while Novo Nordisk's semaglutide is projected to reach approximately $34.606 billion, ranking second [3]